Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure (SERCA-LVAD)

Imperial College London

Status and phase

Terminated

Phase 2

Conditions

Patients That Have Received a Left Ventricular Assist Device

Chronic Heart Failure

Treatments

Genetic: AAV1/SERCA2a

Drug: Placebo

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00534703

2007-002809-48 (EudraCT Number)

CRO782

Details and patient eligibility

About

The aim of the study is to determine the safety and feasibility of giving an adeno-associated viral vector expressing the sarcoplasmic reticulum calcium ATPase (SERCA2a), driven by the CMV promoter (AAV1-CMV-SERCA2a), to heart failure patients that have received a left ventricular assist device (LVAD) for an accepted clinical indication.

Full description

It is a randomised, double-blind study of 24 patients that will be randomised to receive either the study drug (AAV1.SERCA2a) or placebo.

The purpose of gene transfer of SERCA2a is to improve systolic and diastolic function of the failing ventricle. Studies show that reduction of SERCA2a in failing ventricle is a key factor in depression of contraction, and that restoration of SERCA2a levels can improve function to near normal levels. The vector will be delivered during a cardiac catheterisation procedure by a 10-minute infusion into the coronary arteries.

Myocardial tissue is obtained at the time of LVAD placement, as a routine part of device implantation. Further samples will be obtained when the heart is transplanted or the LVAD removed. Measures of tissue inflammation as well as efficacy of gene transfer will be made by comparing these two samples. Recovery of contractile function of the heart will be assessed during attempts to wean patients from the LVAD using standard protocols.

The results will be assessed in conjunction with two companion studies which will start earlier in the US, one performing SERCA2a gene transfer with the same vector, but delivered by direct injection into the myocardium during LVAD insertion, and one using AAV1-CMV-SERCA2a delivered percutaneously in heart failure patients. The latter has both a dose-ranging and placebo-controlled arm.

Enrollment

5 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

Patients that have had a left ventricular assist device (LVAD) implanted for chronic heart failure, where chronic heart failure is defined as at least 6 months
Patients are clinically stable in the opinion of the clinical team looking after the patient
Written informed consent

Exclusion criteria

<18 or >70 years of age at the time of consent
Pregnancy or within 6 months of giving birth
Women of child-bearing potential not using an effective method of contraception
Men not using an effective method of contraception
Suspected or active viral, fungal or parasitic infection within 48 hours prior to administration of IMP, in the opinion of the investigator*.
Patients at a high risk of thrombosis in the opinion of the investigator
Patients with a previous episode of LVAD thrombosis
Patients with persistently raised lactate dehydrogenase (LDH >2.5 ULN)
Patients requiring triple anticoagulation i.e. warfarin and dual anti-platelet
Patients participating in another clinical trial
Patients unable to comply with the protocol mandated procedures for social or other reasons, in the opinion of the investigator and primary care physician
- Eligible, enrolled and randomised patients who develop an infection will have study treatment delayed until 7 or more days after the time point when infection is no longer clinically evident.